Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Minerva Cardioangiologica

Volumn 50, Issue 5, 2002, Pages 547-553

  Quinn, M J ^a   Moliterno, D J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angina, unstable; Coronary disease; Platelet aggregation inhibitors; Platelet glycoprotein GP IIb IIIa complex

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; TIROFIBAN; TROPONIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG POTENCY; FEMALE; GENDER; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; META-ANALYSIS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SEX FACTORS; THROMBOCYTOPENIA; TIME FACTORS; TROPONIN;

EID: 0036807267     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation 2000;102:118-22.
2. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227-31.
3. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201-6.
4. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352: 87-92.
5. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-44.
6. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
7. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
8. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
9. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 1991;614:193-213.
10. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80:11B-20B.
11. Lele M, Sajid M, Wajih N, Stouffer GA. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001;104: 582-7.
12. Coller BS. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions Thromb Haemost 1999;82: 326-36.
13. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97: 1680-8.
14. Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD et al. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001;103:1488-91.
15. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1905-14.
16. The PARAGON B Investigators. Randomized, placebo-controlled trial of titrated intravenous iamifiban for acute coronary syndromes. Circulation 2002;105: 316-21.
17. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999;340:1623-9.
18. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management Lancet 1999;354: 1757-62.
19. Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation 2001;103:2891-6.
20. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998;97:2386-95.
21. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
22. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101:2557-67.
23. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C et al. Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non-ST-Segment-Elevation Acute Coronary Syndromes. Circulation 2001;104:2767-71.
24. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-8.
25. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478-85.
26. Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999;100:1509-14.
27. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
28. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000;356:9-16.
29. Zhao X-Q, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: angiographic results from the PRISM-PLUS trial (platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). Circulation 1999;100:1609-15.
30. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial investigators. Circulation 2000;102:1101-6.
31. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
32. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina) 2002.